Antiviral prophylaxis for hepatitis B virus reactivation in T‐cell lymphoma patients with resolved hepatitis B virus infection

Documenti analoghi

• Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B
  di: Joohyun Hong, et al.
  Pubblicazione: (2024)
• Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma
  di: Fang Liu, et al.
  Pubblicazione: (2024)
• Genome‐wide loss‐of‐function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus‐integrated hepatoma cells
  di: Makoto Fukuoka, et al.
  Pubblicazione: (2024)
• Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus‐related hepatocellular carcinoma
  di: Liming Qin, et al.
  Pubblicazione: (2024)
• HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy
  di: Jian Liu, et al.
  Pubblicazione: (2024)